Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: A new paradigm for use

Pediatrics

Volumn 122, Issue 6, 2008, Pages

  Paller, Amy S ^a,f   Eichenfield, Lawrence F ^b   Kirsner, Robert S ^c   Shull, Toni ^d   Jaracz, Eileen ^d   Simpson, Eric L ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f NONE   (United States)

Author keywords

Atopic dermatitis; Intermittent dosing; Tacrolimus ointment; Topical calcineurin inhibitors; Topical corticosteroids

Indexed keywords

ALCLOMETASONE; ALCLOMETASONE DIPROPIONATE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; APPLICATION SITE BURNING; APPLICATION SITE INFECTION; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FEMALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHOOL CHILD; AGE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; OINTMENT; PROBABILITY; RECURRENT DISEASE; RISK ASSESSMENT; SEX DIFFERENCE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIVARIATE ANALYSIS; OINTMENTS; PROBABILITY; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 58249087940     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-1343     Document Type: Article

References (28)

1. Horii KA, Simon SD, Liu DY, Sharma V. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics. 2007;120(3). Available at: www.pediatrics.org/cgi/content/full/120/3/e527
2. Chamlin SL, Frieden LT, Williams ML, Chren MM. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114(3):607-611
3. Abramovits W, Hung P, Tong KB. Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis. Am J Clin Dermatol. 2006;7(4):213-222
4. Boguniewicz M, Abramovits W, Paller A, et al. A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis. J Drugs Dermatol. 2007;6(4):416-423
5. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1): 1-15
6. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol. 2004; 151(suppl 70):3-27
7. Hanifin JM, Paller AS, Eichenfield L, et al. Long-term (up to 4 years) efficacy and safety of tacrolimus ointment in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53(2 Suppl 2):S186-S194
8. Koo JY, Fleischer AB, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8,000 patients. J Am Acad Dermatol. 2005;53(2 Suppl 2):S195-S205
9. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM; Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44(1 Suppl):S58-S64
10. Mori M, Pimpinelli N, Giannotti B. Topical corticosteroids and unwanted local effects: improving the benefit/risk ratio. Drug Saf. 1994;10(5):406-412
11. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids: a review. Drugs. 1988; 36(suppl 5):51-61
12. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M; Tacrolimus Ointment Study Group. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(1 Suppl): S47-S57
13. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):539-546
14. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacroli-mus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. Allergy Clin Immuno1. 1998; 102(4 pt 1):637-644
15. Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005; 52(5):810-822
16. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150(3):554-562
17. Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol. 2007;87(1):54-61
18. Kang S, Paller A, Soter N, Satoi Y, Rico MJ, Hanifin JM. Safe treatment of head/neck AD with tacrolimus ointment. J Der-matolog Treat. 2003;14(2):86-94
19. Freeman AK, Serle J, VanVeldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis. 2004;73(4): 267-271
20. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53(1 Suppl 1):S50-S58
21. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol. 2002;147(3): 528-537
22. Boguniewicz M, Leung DY. Atopic dermatitis. J Allergy Clin Immunol. 2006;117(2 suppl Mini-Primer):S475-S480
23. Breneman D, Fleischer AB Jr, Abramovits W, et al. An innovative approach to flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of three times weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58(6):990-999
24. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;(suppl 92):44-47
25. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinet-ics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J Drugs Dermatol. 2007;6(2):185-193
26. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol. 2005;124(4):695-699
27. Alaiti A, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol. 1998;38(1):69-76
28. Rico MJ, Paller AS. APPLES: A prospective pediatric longitudinal evaluation to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis. Poster presented at the 21st World Congress of Dermatology; September 30 to October 5, 2007; Buenos Aires, Argentina